Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:GALT NASDAQ:NEPT NASDAQ:OASM NASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.28$0.07▼$5.84$2.92M2.074.66 million shs22.99 million shsGALTGalectin Therapeutics$2.25+7.7%$1.69$0.73▼$3.90$132.28M0.7411,656 shs259,127 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/ATHTXTheratechnologies$3.14$2.63$1.12▼$3.20$144.38M0.55886,365 shs914,094 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%-71.01%-96.38%GALTGalectin Therapeutics+7.66%+3.69%+70.45%+74.42%-5.06%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-59.92%THTXTheratechnologies0.00%+33.05%+20.77%+136.09%+105.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFMDAffimed2.9277 of 5 stars4.00.00.04.30.60.01.3GALTGalectin Therapeutics1.0989 of 5 stars3.50.00.00.00.61.70.0NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.00Hold$3.621,895.87% UpsideGALTGalectin Therapeutics 3.00Buy$6.00166.67% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/AOASMOasmia Pharmaceutical AB (publ) 0.00N/AN/AN/ATHTXTheratechnologies 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest GALT, AFMD, NEPT, THTX, and OASM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/14/2025AFMDAffimedCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025AFMDAffimedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/13/2025AFMDAffimedLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025AFMDAffimedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.105/13/2025AFMDAffimedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.394/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00OASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03THTXTheratechnologies$88.67M1.63N/AN/A($0.55) per share-5.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/AOASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/ATHTXTheratechnologies-$8.31M-$0.08N/A44.86N/A-4.18%N/A-0.37%N/ALatest GALT, AFMD, NEPT, THTX, and OASM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/9/2025Q2 2025THTXTheratechnologies-$0.01-$0.01N/A-$0.09$24.30 million$17,729.00 billion5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93GALTGalectin TherapeuticsN/A0.080.08NEPTNeptune Wellness SolutionsN/A0.230.10OASMOasmia Pharmaceutical AB (publ)N/A0.800.73THTXTheratechnologiesN/A1.080.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%GALTGalectin Therapeutics11.68%NEPTNeptune Wellness Solutions14.44%OASMOasmia Pharmaceutical AB (publ)0.11%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%GALTGalectin Therapeutics50.10%NEPTNeptune Wellness Solutions5.10%OASMOasmia Pharmaceutical AB (publ)N/ATHTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableGALT, AFMD, NEPT, THTX, and OASM HeadlinesRecent News About These CompaniesTheratechnologies (NASDAQ:THTX) Announces Quarterly Earnings ResultsJuly 9 at 9:11 AM | marketbeat.comTheratechnologies Reports Financial Results for the Second Quarter 2025July 9 at 7:30 AM | globenewswire.comTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7 at 1:19 PM | seekingalpha.comTheratechnologies (NASDAQ:THTX) Stock Rating Lowered by Jones TradingJuly 5, 2025 | americanbankingnews.comFuture Pak to buy Theratechnologies for $254 millionJuly 4, 2025 | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3, 2025 | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3, 2025 | cantechletter.comCTheratechnologies to be bought by CB Biotechnology for $254MJuly 3, 2025 | msn.comTheratechnologies to Announce Second Quarter 2025 Financial ResultsJuly 3, 2025 | globenewswire.comTheratechnologies' (THTX) Hold Rating Reaffirmed at Jones TradingJuly 3, 2025 | marketbeat.comTheratechnologies to be Acquired by Future Pak AffiliateJuly 2, 2025 | tipranks.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2, 2025 | finance.yahoo.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2, 2025 | globenewswire.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 29, 2025 | globenewswire.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2, 2025 | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, AFMD, NEPT, THTX, and OASM Company DescriptionsAffimed NASDAQ:AFMD$0.18 -0.10 (-34.95%) As of 05/19/2025Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Galectin Therapeutics NASDAQ:GALT$2.25 +0.16 (+7.66%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$2.20 -0.04 (-2.00%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Oasmia Pharmaceutical AB (publ) NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Theratechnologies NASDAQ:THTX$3.14 0.00 (0.00%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$3.14 +0.00 (+0.16%) As of 06:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
